Account

From launching your product to training your team

Remap Consulting is the pricing and market access launch partner to help you launch with confidence.

Launch Implementation

Develop and implement a pricing and market access launch strategy for your product

Learn more

Price Optimization

Having the right pharma pricing strategy is essential for your product to optimize revenues.

Learn more

Price & Market Access Training

We aim to make the transfer of knowledge more flexible, effective, and engaging.

Learn more

We work with people who’re asking:

Optimal price
What is the optimal price for our product?
Right evidence
Do we have the right evidence to support price and access to launch?
Training people
Do we have the right capabilities to train people on market access?
Market access potential
What is the pricing and market access potential for BD opportunities?

Discover client success stories

Case studies

Biosimilar country pricing and market access

Our client wanted to gain a better understanding of current and forthcoming policy measures affectin…
Read more

Developing a tender strategy for a rare disease

The company found themselves facing competitive tenders for the first time in this disease space – t…
Read more

Discover the latest insights

Reforming Health Technology Assessments to Embrace…
The advent of cell and gene therapies (CGTs) represents a paradigm shift in medicine, offering the p…
Read more
EU HTA process
ISPOR Europe 2024
We’re delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We’ll…
Read more
EU HTA process
ISPOR Europe 2024: How Could ATMP’s Demonstr…
This study examines how Advanced Therapy Medicinal Products (ATMPs) demonstrate economic benefit for…
Read more
UK
World’s first CRISPR-based Gene Therapy Exa-cel …
NICE recommends gene therapy for severe beta-thalassaemia, offering hope for improved quality of lif…
Read more
UK
Hemgenix becomes the first treatment to enter NHS …
New ground-breaking gene therapy for haemophilia B enters NHS England’s Innovative Medicines Fund, o…
Read more
UK
NICE Approves CAR-Therapy for NHS
NICE recommends Kymriah® for routine NHS use, offering immense benefits for those with resistant B-…
Read more
market access
Does price vs volume rule apply for CAR-Ts conside…
We explore CAR T-cell therapy challenges, regulatory approvals, market growth, pricing models, and a…
Read more
market access
How will recent safety signals impact patient acce…
Safety signals have sparked vital discussions on patient access to ATMPs, marking a pivotal moment i…
Read more
Advanced Therapies Congress 2024: How could ATMPs …
Objectives The objective of this study is to explore the role of economic benefit in the HTA decisio…
Read more
Reflecting on the Pricing & Market Access tre…
Back in January this year, we summarised the key trends our market access experts believed would dom…
Read more

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch